Mei Z.,N03 Peoples Hospital Of Zhengzhou |
Yanhua Z.,N03 Peoples Hospital Of Zhengzhou |
Weiyan G.,N03 Peoples Hospital Of Zhengzhou |
Hongxia H.,N03 Peoples Hospital Of Zhengzhou |
And 2 more authors.
Cancer Research and Clinic | Year: 2014
Objective: To evaluate the efficacy and safety profile of S-1 combined with oxaliplatin L-OHP (SOX) in the treatment of locally advanced or metastatic colorectal cancer. Methods: 70 patients with advanced or metastatic colorectal cancer were randomly divided into trial group (35 cases) and control group (35 cases). The trail group was administered with dose of 130 mg/m2 L-OHP, plus S-1 which was given orally with body surface area (BSA) (BSA<1.25 m2, 80 mg/d; BSA≥1.25 m2 and <1.5 m2, 100 mg/d; BSA≥1.50 m2 and <1.8 m2, 120 mg/d; BSA>1.8 m2, 140 mg/d). This schedule was repeated every 3 weeks. The control group treated by FOLFOX4 regimen (L-OHP was given on d1 with 80 mg/m2 through intravenous, leucovorin was intravenously on d1, 2, with 200 mg/m2, 5-Fu was intravenously injected on d1, 2, with 400 mg/m2, and was administered intravenously 44 hours with 1 200 mg/m2 on d1). This schedule was repeated every 2 weeks. Results: The total clinical effective rate had no significant difference in the trail group and control group (51.4 %, 18/35 vs 45.7 %, 16/35) (χ2 = 0.229, P = 0.632). Toxicity, nausea and vomiting rate in the trail group were lower than those in the control group (48.5 %, 16/35 vs 71.4 %, 25/35, 68.6 %, 24/35 vs 88.6 %, 31/35, P < 0.05), but hand-foot syndrome and peripheral neurotoxicity rates had no significant difference between two groups (P > 0.05). Weight increased significantly after chemotherapy treatment in the two groups (t = 2.702 5, P = 0.003 9). Conclusion: SOX regimen is feasible and safe for advanced colorectal cancer.